Solid Tumors Clinical Trials

A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 919 clinical trials
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

The purpose of this study is to investigate efficacy and safety of Lenalidomide in combination with R-GemOx as first-line treatment of elderly patients with Diffuse large B cell lymphoma.

b-cell lymphoma
lenalidomide
hiv related lymphoma
gemox
diffuse large b-cell lymphoma
  • 0 views
  • 19 Feb, 2024
  • 1 location
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Background People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers. They want to test 2 drugs that, taken separately, have helped people with non-rare cancers. They want to see if these drugs …

merkel cell carcinoma
thymic carcinoma
neuroendocrine tumor
adenocarcinoma
serous cystadenocarcinoma
  • 0 views
  • 19 Feb, 2024
  • 1 location
PSMA-specific CAR-T Cell Therapy

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of PSMA-specific CAR-T cell therapy in patients with PSMA positive tumor. Another goal of the study is to learn more about the function of the PSMA CAR-T cells and their persistency in the patients.

  • 0 views
  • 19 Feb, 2024
  • 4 locations
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.

Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy. A locally unresectable tumor (locally advanced pancreatic cancer (LAPC)) is present in 30% of the cases and is defined as a surgically unresectable tumor encasing the adjacent arteries [celiac …

gilbert's syndrome
teratogenicity
immunosuppressant
adenocarcinoma
tumor burden
  • 0 views
  • 24 Nov, 2025
  • 1 location
NBE-002 in Patients With Advanced Solid Tumors

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.

systemic therapy
solid tumor
blood coagulation tests
solid tumour
advanced solid tumor
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Eligibility Adults age 18 and older with pancreatic cancer, breast cancer, or a solid tumor that has not been cured by standard therapies. Also, children age 12-17 with a solid tumor (other than a muscle tumor) with no standard therapy options.

gilbert's syndrome
solid tumor
blood transfusion
muscle tumor
MRI
  • 0 views
  • 24 Nov, 2025
  • 1 location
A Study of SGN-B6A in Advanced Solid Tumors

It will also study whether SGN-B6A works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-B6A should be given to participants. Part B will use the dose found in Part A to find out how safe SGN-B6A is …

adenocarcinoma
solid tumour
breast cancer
ovarian cancer
measurable disease
  • 0 views
  • 19 Feb, 2024
  • 3 locations
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.

  • 0 views
  • 22 Aug, 2025
  • 2 locations
A Study of SY 5609 a Selective CDK7 Inhibitor in Advanced Solid Tumors

This is a dose escalation study and will be the first to administer SY-5609 alone to humans with select advanced solid tumors and in combination with Fulvestrant to patients with HR positive, HER2-negative breast cancer.

human chorionic gonadotropin
solid tumor
fulvestrant
her2/neu-negative breast cancer
solid tumour
  • 0 views
  • 19 Feb, 2024
  • 5 locations
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of BPI-1178 in subjects with advanced solid tumor, as well as the subjects with advanced hormone receptor-positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer.

international normalized ratio
systemic therapy
solid tumor
aptt
epidermal growth factor receptor
  • 0 views
  • 19 Feb, 2024
  • 1 location